title: Tucaresol down-modulation of MUC1-stimulated human mononuclear cells.
abstract: Interaction between antigen presenting cells and T lymphocytes, through receptors and co-stimulatory molecules present on the surface of these cells, is one of the key means to modulate the adaptive immune system. Tucaresol, a Schiff-base-forming chemical, can be used as a substitute for the physiological donor of carbonyl groups of antigen presenting cells, which can interact with the amine groups of T lymphocytes to modulate the adaptive immune system. This study was done to determine whether tucaresol can enhance killing of cancer cells in vitro as well as protect non-obese diabetic severe combined immunodeficient mice from tumor development by mucin 1 stimulated human mononuclear cells through the adaptive immune system. The expected hypothesis was not supported. Percent specific lysis of MCF-7 tumor cells by mucin 1 stimulated human mononuclear cells was reduced by tucaresol. Furthermore, tucaresol abolished the protective effect of mucin 1 stimulated human mononuclear cells against MCF-7 breast cancer cell growth in non-obese diabetic severe combined immunodeficient mice. This study implies that tucaresol may be of use as an immunosuppressive agent.
authors.affiliation: Women's Health Research Institute, Department of Internal Medicine, Texas Tech University Health Sciences Center , Amarillo, Texas, 79106 , USA .
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Wright
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Rewers-Felkins
authors.forename: Nazrul I
authors.initials: NI
authors.lastname: Chowdhury
authors.forename: Jewel
authors.initials: J
authors.lastname: Ahmed
authors.forename: Sanjay K
authors.initials: SK
authors.lastname: Srivastava
authors.forename: Pamela R
authors.initials: PR
authors.lastname: Lockwood-Cooke
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects* / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001547:Benzaldehydes / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D054992:Immunological Synapses / Q000378:metabolism; D007165:Immunosuppression Therapy; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D061986:MCF-7 Cells; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D018396:Mucin-1 / Q000276:immunology; D050050:Protein Carbonylation; D013601:T-Lymphocytes / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000951:Antigens, Neoplasm; D001547:Benzaldehydes; D001565:Benzoates; D018396:Mucin-1; C059629:tucaresol